- Home
- ELEV
as 05-20-2024 11:33am EST
$.
+$.
+.%
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
| Founded: | 2019 | Country: | United States |
| Employees: | 29 | City: | BOSTON |
| Market Cap: | 197.2M | IPO Year: | 2021 |
| Target Price: | $7.40 | AVG Volume (30 days): | 963.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $5.89 | Next Earning Date: | 05-02-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Elevation Oncology Inc. Common stock News
ELEV Breaking Stock News: Dive into ELEV Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target
PR Newswire
13 days ago
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
PR Newswire
18 days ago
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
PR Newswire
a month ago
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
GuruFocus.com
2 months ago
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
PR Newswire
2 months ago
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
InvestorPlace
3 months ago
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
PR Newswire
3 months ago